SCHEMBL1114138

SCHEMBL1114138

Fc1cccc(N2CCN(CCCCOc3ccc(Cn4cncn4)cc3)CC2)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 7/20 0.49
HRH1 P35367 6/20 0.49
HTR1A P08908 6/20 0.49
HTR2A P28223 6/20 0.49
DRD3 P35462 6/20 0.49
TMEM97 Q5BJF2 3/20 0.49
SIGMAR1 Q99720 3/20 0.49
SLC6A2 P23975 1/20 0.47
SLC6A4 P31645 1/20 0.47
HRH3 Q9Y5N1 6/20 0.45
HRH2 P25021 2/20 0.45
DRD1 P21728 2/20 0.45
DRD5 P21918 1/20 0.45
ALDH1A1 P00352 2/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
HTR2C P28335 1/20 0.43
USP2 O75604 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27825969 0.89 KCNH2 (0.57) DRD2HRH1HTR1AHTR2ADRD3
SCHEMBL1114455 0.81 DRD2 (0.51) DRD2HTR1AHTR2ADRD3SLC6A2
Hydrochloric Acid SCHEMBL27805479 0.80 KCNH2 (0.56) DRD2HRH1HTR1AHTR2ASIGMAR1
SCHEMBL1114442 0.77 LMNA (0.64) DRD2HTR1AHTR2ADRD3SLC6A2
SCHEMBL11278328 0.73 HRH1 (0.58) DRD2HRH1HTR1AHTR2ADRD3
SCHEMBL10865799 0.72 DRD2 (0.64) DRD2HRH1HTR1AHTR2ADRD3
SCHEMBL5178875 0.72 KCNH2 (0.57) DRD2HRH1HTR1AHTR2ADRD3
SCHEMBL27805478 0.72 KCNH2 (0.57) DRD2HTR1AHTR2ADRD3ALDH1A1
SCHEMBL1114848 0.72 HTR1A (0.66) DRD2HTR1AHTR2ADRD3SLC6A2
Hydrochloric Acid SCHEMBL1114721 0.71 HTR1A (0.65) DRD2HTR1AHTR2ADRD3SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2279179-B1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2014-09-17 EP claimed
US-8772299-B2 Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-07-08 US claimed
CN-102046610-B Phenyl piperazine compounds, pharmaceutical composition including the same, and use thereof SK HOLDINGS CO LTD 2013-06-05 CN claimed
US-7985752-B2 Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof SK HOLDINGS CO., LTD. (KR) 2011-07-26 US claimed
US-20110118264-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2011-05-19 US claimed
CN-102046610-A Phenyl piperazine compounds, pharmaceutical composition including the same, and use thereof SK HOLDINGS CO LTD 2011-05-04 CN claimed
EP-2279179-A2 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF SK Holdings Co., Ltd. (KR) 2011-02-02 EP claimed
US-20090298831-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-12-03 US claimed
WO-2009145591-A2 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2009-12-03 WO claimed
EP-2279179-B1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2014-09-17 EP disclosed
EP-2279179-B1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2014-09-17 EP disclosed
US-8772299-B2 Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-07-08 US disclosed
US-8772299-B2 Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-07-08 US disclosed
US-8772299-B2 Phenyl piperazine compounds, pharmaceutical composition including the same and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-07-08 US disclosed
EP-2279179-A2 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF SK Holdings Co., Ltd. (KR) 2011-02-02 EP disclosed
US-20090298831-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-12-03 US disclosed
US-20090298831-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-12-03 US disclosed
US-20090298831-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-12-03 US disclosed
WO-2009145591-A2 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2009-12-03 WO disclosed
WO-2009145591-A2 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME, AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298831-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF HTR5A, HTR1A, HTR2A DRD2 62/4885HRH1 111/4885HTR1A 2/4885
US-20110118264-A1 PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION INCLUDING THE SAME AND USE THEREOF HTR5A, HTR1A, HTR2A DRD2 60/4885HRH1 110/4885HTR1A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.